Over the past ten years, CRACK IT Challenges has spearheaded the development of innovative 3Rs technologies through a growing portfolio of products and services that deliver improved scientific data, more predictive models and reduce the reliance on animals. From non-invasive home cage monitoring and human relevant stem cell models to in silico platforms, approaches developed through CRACK IT are delivering real world scientific and 3Rs benefits across multiple industry sectors and in basic research.
We are launching two Challenges for 2021 that tackle areas of significant scientific need and 3Rs potential. These include our first Mega-Challenge, which represents a leap forward in the size of the problem a Challenge addresses and supports this with increased funding and award duration. Further information about the CRACK IT Challenges competition process can be found on our Innovation Platform.
Join our webinars
We are hosting webinars on Tuesday 7 and Thursday 9 September to launch the 2021 CRACK IT Challenges. Each webinar will focus on a specific Challenge and will give you an opportunity to learn more about the competition, ask the Sponsors questions and find out how to submit a competitive application. Links to register for each webinar can be found below.
Challenge 40: Virtual Second Species
Towards a Virtual Second Species in Toxicology for Drug Development
Our first Mega-Challenge aims to apply advanced computational and mathematical modelling approaches including Machine Learning, systems biology, systems toxicology and multi-scale modelling to develop a suite of virtual dog tissues and organs to model toxicological endpoints for new medicines. The model developed will provide a tool to start moving towards replacing the use of the dog as a second species in drug development.
Three Phase Mega-Challenge
Sponsors: Bayer AG, Eli Lilly and Company, Genentech Inc., Gilead Sciences Inc., GSK, Merck Healthcare KGaA and Roche
Innovative Safety Assessment of Fish adverse Effects
Environmental risk assessment evaluates the likelihood that the environment may be impacted by exposure to one or more chemical stressors and is assessed across three trophic levels, with fish used as the vertebrate species when in vivo testing is required. This Challenge aims to develop a suite of innovative, scalable bioassays for key adverse outcome pathways to replace in vivo fish studies in chemical safety screening and regulatory environmental risk assessment.
Two Phase Challenge
Sponsors: Bayer AG, AstraZeneca and Unilever
Partners: Department for Environment, Food and Rural Affairs (DEFRA), the Health and Safety Executive and the Environment Agency